EJMK Ventures LLC Acquires Shares of 7,812 AbbVie Inc. $ABBV

Key Points

• EJMK Ventures LLC bought a new stake in AbbVie in the fourth quarter, purchasing 7,812 shares valued at about $1.785 million. The position makes AbbVie 1.1% of the fund’s holdings.
• AbbVie continues to attract strong institutional interest, with several large funds increasing their positions and 70.23% of the stock now owned by institutional investors. Analysts are also broadly positive, with a consensus rating of Moderate Buy and an average price target of $253.43.
• The company reported better-than-expected quarterly results, posting $2.65 EPS and $15 billion in revenue, while also declaring a quarterly dividend of $1.73 per share. Recent news also highlights possible pipeline and growth support, including a reported near-$11 billion acquisition of Apogee Therapeutics.

EJMK Ventures LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 7,812 shares of the company's stock, valued at approximately $1,785,000. AbbVie accounts for 1.1% of EJMK Ventures LLC's holdings, making the stock its 20th largest position.

A number of other hedge funds also recently added to or reduced their stakes in ABBV. Norges Bank acquired a new position in AbbVie during the 4th quarter worth $5,865,055,000. Wellington Management Group LLP lifted its holdings in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Capital World Investors boosted its position in shares of AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company's stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares in the last quarter. Cardano Risk Management B.V. raised its holdings in shares of AbbVie by 914.6% in the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock worth $1,244,112,000 after purchasing an additional 4,908,260 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ABBV. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 price target on the stock. Bank of America raised AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price target on the stock in a research note on Thursday, April 30th. Morgan Stanley upped their price objective on shares of AbbVie from $270.00 to $278.00 and gave the company an "overweight" rating in a research note on Thursday, April 30th. Cantor Fitzgerald reissued an "overweight" rating and issued a $240.00 target price on shares of AbbVie in a research report on Thursday, April 30th. Finally, BMO Capital Markets restated an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $253.43.

AbbVie Stock Performance

NYSE:ABBV opened at $216.63 on Friday. The company has a market capitalization of $382.74 billion, a P/E ratio of 106.71, a P/E/G ratio of 0.66 and a beta of 0.32. The stock's 50 day moving average price is $212.18 and its 200 day moving average price is $218.76. AbbVie Inc. has a 52 week low of $181.73 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company's revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.46 earnings per share. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie's payout ratio is currently 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.